Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Oxaliplatin is a third-generation platinum derivative used for metastatic or advancedcolorectal cancer treatment. Although myelosuppression is the most common causeof oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immunemediatedthrombocytopenia are reported. We report a case of a 57-year-old womanwith colon cancer who developed gum bleeding and petechiae after oxaliplatininfusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within4 days with no recurrence following discontinuation of oxaliplatin. Physicians need tobe aware of the risk of severe acute thrombocytopenia following oxaliplatinadministration.
Abstract
Oxaliplatin is a third-generation platinum derivative used for metastatic or advancedcolorectal cancer treatment. Although myelosuppression is the most common causeof oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immunemediatedthrombocytopenia are reported. We report a case of a 57-year-old womanwith colon cancer who developed gum bleeding and petechiae after oxaliplatininfusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within4 days with no recurrence following discontinuation of oxaliplatin. Physicians need tobe aware of the risk of severe acute thrombocytopenia following oxaliplatinadministration.
참고문헌 (13)
- Andre T, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", N Engl J Med, 350, pp.2343~2351 (2004)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- Kanemitsu Y, "A randomized phase II", III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer : Japan Clinical Oncology Group Study JCOG0603, 2009, pp.39, 406~409
- Wu Y, "Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007", 2009;31 Pt, 2, pp.2416~2432
- Jardim DL, "Oxaliplatin-related thrombocytopenia", Ann Oncol, 23, pp.1937~1942 (2012)
- Bautista MA, "Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin : two case reports and a review of the literature", J Hematol Oncol, 3, pp.12~ (2010)
- Colucci G, "Phase III randomized trial of FOLFIRI versus FOLFOX4in the treatment of advanced colorectal cancer : a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale", J Clin Oncol, 23, pp.4866~4875 (2005)
- Taleghani BM, "Oxaliplatin-induced immune pancytopenia", Transfusion, 45, pp.704~708 (2005)
- Curtis BR, "Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin", Am J Hematol, 81, pp.193~198 (2006)
- Pavic M, "Oxaliplatin-induced immune thrombocytopenia", Gastroenterol Clin Biol, 30, pp.797~798 (2006)
- Fontao-Wendel R, "Immune-mediated pancytopenia induced by oxaliplatin : a case report", Transfusion, 50, pp.1453~1459 (2010)
- Suzuki K, "Oxaliplatin-induced acute thrombocytopenia : a case report and review of the literature", Intern Med, 52, pp.611~615 (2013)
- Ohta S, "Oxaliplatin-induced acute-onset thrombocytopenia and hemorrhage : case report and review of the literature", Oncol Lett, 3, pp.1297~1300 (2012)